Clinical Trials: Result Publication Requirements

Publishing Clinical Trial Results in Peer-Reviewed Journals

Posted on digi By digi

Publishing the results of clinical trials in peer-reviewed journals is a crucial step in the research lifecycle. It transforms raw data into publicly available evidence, informs medical decision-making, and validates the ethical commitment made to trial participants. However, publication involves more than just writing a manuscript—it requires adherence to transparency policies, ethical standards, and scientific rigor.
Click to read the full article.

Clinical Trial Transparency and Ethics, Result Publication Requirements

Timeline and Format for Summary Results Reporting

Posted on digi By digi

Summary results reporting ensures that data from completed clinical trials becomes publicly accessible, whether or not the trial led to publication in a peer-reviewed journal. Regulatory agencies including the FDA, EMA, and WHO member nations require structured summary data submission to promote transparency, reduce publication bias, and fulfill ethical obligations to trial participants.
Click to read the full article.

Clinical Trial Transparency and Ethics, Result Publication Requirements

How to Prepare a Lay Summary of Clinical Trial Results

Posted on digi By digi

Lay summaries—also called plain language summaries—are short, readable documents that communicate the results of a clinical trial to the general public. Required under the EU Clinical Trials Regulation (EU CTR), and encouraged globally, lay summaries increase transparency, uphold participant rights, and promote public understanding of clinical research.
Click to read the full article.

Clinical Trial Transparency and Ethics, Result Publication Requirements

Open Access Policies by Major Medical Journals

Posted on digi By digi

Open access (OA) publishing is transforming the way clinical trial results are shared with the global scientific community and the public. Traditionally, medical journals operated on subscription-based models, limiting the visibility of research. Today, funders, regulators, and journals are driving an unprecedented shift toward open access—making clinical trial data more accessible, transparent, and reusable.
Click to read the full article.

Clinical Trial Transparency and Ethics, Result Publication Requirements

Conflict of Interest Disclosures in Publications

Posted on digi By digi

Conflict of Interest (COI) disclosures are a cornerstone of clinical research transparency. Whether financial or non-financial, real or perceived, any interest that may influence—or appear to influence—the interpretation, reporting, or publication of trial results must be declared. Failure to do so not only undermines scientific credibility but can lead to public mistrust, regulatory sanctions, and journal retractions.
Click to read the full article.

Clinical Trial Transparency and Ethics, Result Publication Requirements

Data Sharing Statements as per ICMJE Guidelines

Posted on digi By digi

In an era emphasizing transparency and reproducibility, data sharing has become a key ethical and regulatory expectation in clinical research. As part of this global movement, the International Committee of Medical Journal Editors (ICMJE) introduced mandatory data sharing statements for clinical trial manuscripts submitted on or after July 1, 2018.
Click to read the full article.

Clinical Trial Transparency and Ethics, Result Publication Requirements

Navigating Delays in Publishing Trial Results

Posted on digi By digi

Publishing the results of clinical trials within a timely frame is both an ethical obligation and a regulatory requirement. Participants contribute their time and health, often with the hope of advancing medical science. When results are delayed—or not published at all—the scientific community suffers from knowledge gaps, patients are denied evidence-based options, and trust in research erodes.
Click to read the full article.

Clinical Trial Transparency and Ethics, Result Publication Requirements

Case Study: Consequences of Delayed Publication

Posted on digi By digi

Delays in publishing clinical trial results are more than administrative oversights—they can undermine trust, impede medical progress, and even jeopardize patient safety. Regulatory frameworks such as FDAAA 801 in the United States and the EU Clinical Trials Regulation (EU CTR) mandate timely dissemination of results. However, compliance is not always met.
Click to read the full article.

Clinical Trial Transparency and Ethics, Result Publication Requirements

Best Practices for Writing Clear and Transparent Results

Posted on digi By digi

Publishing clinical trial results is not merely about data—it’s about communicating findings in a way that is accurate, transparent, and accessible. Regulatory authorities like the FDA, EMA, and Health Canada have strict formats and timelines, while journals and registries demand clarity, consistency, and transparency. Poorly written results can lead to misinterpretation, rejection by journals, regulatory queries, or worse—public misinformation.
Click to read the full article.

Clinical Trial Transparency and Ethics, Result Publication Requirements

GPP Guidelines for Publication Ethics in Trials

Posted on digi By digi

Clinical trial publications shape medical guidelines, regulatory decisions, and patient care. Ethical lapses such as ghostwriting, selective reporting, or sponsor bias can undermine the scientific integrity of published results. To address these concerns, the International Society for Medical Publication Professionals (ISMPP) developed the Good Publication Practice (GPP) guidelines, currently in its third version (GPP3).
Click to read the full article.

Clinical Trial Transparency and Ethics, Result Publication Requirements